Elsevier

Sleep Medicine Reviews

Volume 17, Issue 2, April 2013, Pages 133-142
Sleep Medicine Reviews

Clinical review
Dreaming under antidepressants: A systematic review on evidence in depressive patients and healthy volunteers

https://doi.org/10.1016/j.smrv.2012.05.001Get rights and content

Summary

Sleep related symptoms of depression include sleep fragmentation, early morning awakening, decreased rapid eye movement (REM) sleep latency, increased REM density, and more negative dream content. Most tricyclic antidepressants (ADs) increase total sleep time and decrease wake time after sleep onset, while many selective serotonin reuptake inhibitors (SSRIs) have an opposite effect. However, almost all ADs prolong REM sleep latency and reduce the amount of REM sleep. Case reports and research data indicate a strong effect of ADs on dream recall and dream content. We performed a systematic review (1950 to August 2010) about ADs impact on dreaming in depressive patients and healthy volunteers. Twenty-one clinical studies and 25 case reports were eligible for review and document a clear AD effect on dreaming. The major finding, both in depressed patients and in healthy volunteers, is a decrease of dream recall frequency (DRF) under ADs. This is a rather consistent effect in tricyclic ADs and phenelzine, less consistently documented also for SSRIs/serotonin norepinephrine reuptake inhibitors (SNRIs). Tricyclic ADs induce more positive dream emotions. Withdrawal from tricyclic ADs and from the monoamine oxidase inhibitors phenelzine and tranylcypromine may cause nightmares. Intake and even more withdrawal of SSRIs/SNRIs seem to intensify dreaming, which may be experienced in different ways; a potential to cause nightmares has to be taken into account. Though there are clear-cut pharmacological effects of ADs on DRF and dream content, publications have been surprisingly scarce during the past 60 years. There is evidence of a gap in neuropsychopharmacological research. AD effects on dreams should be recognized and may be used in treatment.

Introduction

Antidepressants (ADs), besides antihyperlipidemic agents and analgesics, are the most prescribed drugs in the U.S.1 In 2006, the prevalence of a lifetime experience of a depressive disorder was 15.7% among U.S. residents aged 18 or older; a 35% increase is expected by 2050.2 The estimated economic burden of depression in the U.S. rose from $77.4 billion in 1990 (inflation-adjusted dollars) to $83.1 billion in 2000.3 Although ADs have a strong impact on sleep and also on dreaming,4, 5 the magnitude and characteristics of AD influence on dreaming have found little attention in efforts to map AD effects.

The importance of ADs is highlighted not only by their therapeutic use for depressive disorders but also by their use in a variety of diseases with impact on the mental state such as insomnia, anxiety disorder, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder, and chronic pain.6, 7 Furthermore, there is an increasing field for cognitive enhancing and lifestyle use of ADs.8

One of the primary features of depression is disordered sleep. At the subjective level, depression is associated with insomnia,9 difficulty in falling asleep, frequent nocturnal awakenings, nonrestorative sleep, and early morning awakening. Reduction of rapid eye movement (REM) sleep latency is one of the most robust and specific features of sleep in depressed patients and considered a trait marker of depression.10, 11, 12 Numerous other polysomnographic features of altered sleep in depression have been documented, such as increases in REM density, duration of first REM sleep period, time of REM sleep, sleep latency, as well as waking time, and decreases in total sleep time, slow wave sleep, sleep continuity, and sleep efficiency.4, 9, 13

Successful improvement of depressive mood by treatment with ADs may be accompanied by different effects on sleep. Triciyclic ADs tend to improve sleep quality and total sleep time,14 while most selective serotonin reuptake inhibitors (SSRIs) tend to cause insomnia and to reduce total sleep time.15 The effects of most ADs on REM sleep are strong and relatively consistent: a prolongation of REM sleep latency and a reduction of REM sleep time.4, 16, 17, 18, 19 In patients with depression and reduced REM latencies, amitryptiline induced REM sleep suppression during the first two treatment nights, correlated with good clinical response.14, 20 However, this finding was not consistently confirmed.21 Monoamine oxidase inhibitors may virtually eliminate REM sleep,19, 22, 23 a phenomenon that neither necessarily produces a positive clinical response in patients nor causes obvious harm.19

The following features have been described in dreams of depressive patients: reduced dream recall frequency (DRF),*24, 25 reduced length of reports,26, 27 dream contents ranging from “mundane”,26, 28 “trivial”,26 to increased “masochistic”,29, 30, 31, 32 vivid, disturbing, and sometimes emerging as nightmares.9 In psychotherapeutic settings, dream content correlated with therapy outcome. In depressed female divorcees, an increase in masochism across the night was a poor prognostic sign.31 Depressed divorcees who incorporated the loss in their dreams and had stronger affects in dreams were finally better adjusted to their new life.33 High masochism scores in dreams of depressed women were related to a decreased likelihood of clinical improvement.32 Even after full clinical remission for at least six months and no chronic use of psychotropic drugs for at least two months, formerly depressive patients still showed significant negative features in REM dreams.30 This included: increased masochism, increased hostility in the environment, more inanimate objects exerting physical effort, more dreaming of the past, and shorter narratives.30

Section snippets

Rationale

Negatively altered dreams are a concomitant phenomenon of depressive disorders. The study of dream in a disease context has a long tradition, primarily in psychoanalysis. After the discovery of REM sleep34 with its undeniable link to dreams and after development of AD drugs, clear-cut data emerged that depression is accompanied by reduced REM sleep latency and increased REM sleep density35 and that most ADs have a strong REM sleep reducing effect. REM sleep reduction by ADs may have a

Methods

A systematic review40 was performed, screening the data sources Ovid MEDLINE, Cochrane Library, PsycNET/PsycINFO, Virtual Health Library, and clinical trial register websites (e.g., clinicaltrials.gov, apps.who.int/trialsearch) for articles in English, German, Spanish, Portuguese, French, and Italian. Used search terms were “dream*(-s, -ing)”, “nightmare*(s)”, and “antidepress*(-ant, -ants, -ive)”, the observation period was 1950 to August 2010. To identify further studies, reference lists of

Results

Using the search terms “dream*(-s, -ing)”, “nightmare*(s)”, and “antidepress*(-ant, -ants, -ive)”, Ovid MEDLINE retrieved 97 abstracts; three of them double citations, 10 reviews, and 35 not fulfilling abstract screening criteria (investigating PTSD 9, medications other than ADs 6, children 5, narcolepsy 4, Parkinson's disease 2, schizophrenia 2, other reasons 7). The remaining 49 papers were full-text screened and 28 full papers were considered suitable for structured data extraction according

Discussion

The reviewed studies document a clear effect of ADs on dream recall and dream content. The major finding is a decrease of DRF under ADs, a rather consistent effect in tricyclic ADs*39, 44, 52 and phenelzine,19, 53 less consistently documented also for SSRIs/SNRIs.*24, *57 ADs reduced DRF both in depressed patients14, 19, 33, 45 and in normal volunteers.35, 44, 49 Administration of SSRIs/SNRIs may increase frequency of nightmares.61 Withdrawal of tricyclic ADs,52, 64 phenelzine,53 and

Conclusions

Considering treatment process, the various classes of ADs have a different potential to reduce DRF, which is accompanied by a spectrum of impact on dream content. Especially in psychotherapy and psychoanalytic dream work in depressed patients, a more personalized approach toward AD pharmacotherapy120 may be implemented, according to patients' needs. Pharmacological effects of ADs, as well as of other psychotropic drugs, on dreaming are theoretically and clinically relevant. They should be

Acknowledgments

The authors declare no conflict of interests. The study received no funding.

References (120)

  • R.M. Whitman et al.

    Drugs and dreams. II. Imipramine and prochlorperazine

    Compr Psychiatry

    (1961)
  • M.O. Akindele et al.

    Mono-amine oxidase inhibitors, sleep and mood

    Electroencephalogr Clin Neurophysiol

    (1970)
  • S.J. Kantor

    Depression: when is psychotherapy not enough?

    Psychiatr Clin North Am

    (1990)
  • P.T. Teman et al.

    Idiopathic rapid-eye-movement sleep disorder: associations with antidepressants, psychiatric diagnoses, and other factors, in relation to age of onset

    Sleep Med

    (2009)
  • Y.E. Ju et al.

    Changing demographics in REM sleep behavior disorder: possible effect of autoimmunity and antidepressants

    Sleep Med

    (2011)
  • National Center for Health Statistics

    Health, United States, 2010: with special feature on death and dying

    (2011)
  • M. Heo et al.

    Population projection of US adults with lifetime experience of depressive disorder by age and sex from year 2005 to 2050

    Int J Geriatr Psychiatry

    (2008)
  • P.E. Greenberg et al.

    The economic burden of depression in the United States: how did it change between 1990 and 2000?

    J Clin Psychiatry

    (2003)
  • M.E. Thase

    Depression, sleep, and antidepressants

    J Clin Psychiatry

    (1998)
  • A. Winokur et al.

    Depression, sleep physiology, and antidepressant drugs

    Depress Anxiety

    (2001)
  • M. Moore et al.

    Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database

    BMJ

    (2009)
  • D.R. Petty et al.

    Prevalence, duration and indications for prescribing of antidepressants in primary care

    Age Ageing

    (2006)
  • C. Elliott

    Pursued by happiness and beaten senseless. Prozac and the American dream

    Hastings Cent Rep

    (2000)
  • J.C. Gillin et al.

    Successful separation of depressed, normal, and insomniac subjects by EEG sleep data

    Arch Gen Psychiatry

    (1979)
  • R.M. Benca et al.

    Sleep and psychiatric disorders. A meta-analysis

    Arch Gen Psychiatry

    (1992)
  • N. Tsuno et al.

    Sleep and depression

    J Clin Psychiatry

    (2005)
  • J.C. Gillin et al.

    The relationship between changes in REM sleep and clinical improvement in depressed patients treated with amitriptyline

    Psychopharmacology (Berl)

    (1978)
  • L. Staner et al.

    Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression

    Sleep

    (1995)
  • H.P. Landolt et al.

    Sleep and sleep electroencephalogram in depressed patients treated with phenelzine

    Arch Gen Psychiatry

    (2001)
  • D.J. Kupfer et al.

    EEG sleep changes as predictors in depression

    Am J Psychiatry

    (1976)
  • D.J. Kupfer et al.

    REM sleep and central monoamine oxidase inhibition

    Psychopharmacologia

    (1972)
  • R.M. Cohen et al.

    REM sleep suppression induced by selective monoamine oxidase inhibitors

    Psychopharmacology (Berl)

    (1982)
  • R. Armitage et al.

    Dream recall and major depression: a preliminary report

    Dreaming

    (1995)
  • M. Schredl

    Dream recall in depressed patients

    Psychother Psychosom Med Psychol

    (1995)
  • D. Riemann et al.

    Investigations of morning and laboratory dream recall and content in depressive patients during baseline conditions and under antidepressive treatment with trimipramine

    Psychiatr J Univ Ott

    (1990)
  • D. Barrett et al.

    Comparison of dream content of depressed vs nondepressed dreamers

    Psychol Rep

    (1992)
  • A.T. Beck et al.

    Dreams of depressed patients. Characteristic themes in manifest content

    Arch Gen Psychiatry

    (1961)
  • P. Hauri

    Dreams in patients remitted from reactive depression

    J Abnorm Psychol

    (1976)
  • R. Cartwright

    Dreams that work: the relation of dream incorporation to adaptation to stressful events

    Dreaming

    (1991)
  • E. Aserinsky et al.

    Regularly occurring periods of eye motility, and concomitant phenomena, during sleep

    Science

    (1953)
  • D. Riemann et al.

    Depression and sleep–the status of current research

    Fortschr Neurol Psychiatr

    (1994)
  • S. Wilson et al.

    Antidepressants and sleep: a qualitative review of the literature

    Drugs

    (2005)
  • L. Fonzi

    L'esperienza del sogno in pazienti depressi e le modificazioni indotte dal trattamento con farmaci antidepressivi

    Rivista di psichiatria

    (2007)
  • J.A. Hobson

    Drugs and dreams

  • A. Liberati et al.

    The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

    BMJ

    (2009)
  • D.F. Thompson et al.

    Drug-induced nightmares

    Ann Pharmacother

    (1999)
  • E.F. Pace-Schott

    Serotonin and dreaming

  • E. Hartmann et al.

    Long-term psychotropic drug administration: effects on dream content and dream density

    Sleep Res

    (1974)
  • M. Kramer et al.

    Drugs and dreams 3. The effects of imipramine on the dreams of depressed patients

    Am J Psychiatry

    (1968)
  • E. Bollea et al.

    Attività onirica dei depressi

    Archivio di psicologia, neurologia e psichiatria

    (1978)
  • Cited by (57)

    • Neurobiology of dreams

      2023, Encyclopedia of Sleep and Circadian Rhythms: Volume 1-6, Second Edition
    • Therapeutic and adverse drug effects

      2023, Encyclopedia of Sleep and Circadian Rhythms: Volume 1-6, Second Edition
    • Trauma survivors with disrupted sleep generate less specific and less emotional autobiographical memories

      2021, Journal of Affective Disorders Reports
      Citation Excerpt :

      Other general exclusion criteria were: (a) history of alcohol or other substance abuse, (b) age < 25 years or > 40 years, (c) current prescription for sedative or psychoactive medication, (d) experience of trauma > 5 years or < 6 months prior to study enrolment, and (e) history of neurological insult. We set these criteria in place to minimize potential confounds related to altered sleep patterns and/or impaired memory processing as a consequence of factors not examined here (Brower, 2001; Chokroverty and Nobili, 2017; Espiritu, 2008; Foral et al., 2011; Grima et al., 2016; Hasler et al., 2012; Ohayon et al., 2004; Teicher et al., 2016; Tribl et al., 2013). Ultimately, 60 women whom we screened met criteria for participation.

    View all citing articles on Scopus
    d

    Tel.: +49 9419415068.

    e

    Tel.: +49 62117031782.

    The most important references are denoted by an asterisk.

    View full text